A note on the Penon definition of nn-category

We show that doubly degenerate Penon tricategories give symmetric rather than braided monoidal categories. We prove that Penon tricategories cannot give all tricategories, but we show that a slightly modified version of the definition rectifies the situation. We give the modified definition, using non-reflexive rather than reflexive globular sets, and show that the problem with doubly degenerate tricategories does not arise.Comment: 14 pages, to appear in Cahiers de Topologie et Geometrie Differentielle Categorique

Higher order semiparametric frequentist inference with the profile sampler

We consider higher order frequentist inference for the parametric component of a semiparametric model based on sampling from the posterior profile distribution. The first order validity of this procedure established by Lee, Kosorok and Fine in [J. American Statist. Assoc. 100 (2005) 960--969] is extended to second-order validity in the setting where the infinite-dimensional nuisance parameter achieves the parametric rate. Specifically, we obtain higher order estimates of the maximum profile likelihood estimator and of the efficient Fisher information. Moreover, we prove that an exact frequentist confidence interval for the parametric component at level $\alpha$ can be estimated by the $\alpha$-level credible set from the profile sampler with an error of order $O_P(n^{-1})$. Simulation studies are used to assess second-order asymptotic validity of the profile sampler. As far as we are aware, these are the first higher order accuracy results for semiparametric frequentist inference.Comment: Published in at http://dx.doi.org/10.1214/07-AOS523 the Annals of Statistics (http://www.imstat.org/aos/) by the Institute of Mathematical Statistics (http://www.imstat.org

Effects of RANKL-Targeted Therapy in Immunity and Cancer.

The role of the receptor activator of nuclear factor-κB ligand (RANKL)/RANK system is well characterized within bone, where RANKL/RANK signaling mediates osteoclastogenesis and bone resorption. However, this system has also been shown to influence biologic processes beyond the skeletal system, including in the immune system and in cancer. RANKL/RANK signaling is important in lymph-node development, lymphocyte differentiation, dendritic cell survival, T-cell activation, and tolerance induction. The RANKL/RANK axis may also have direct, osteoclast-independent effects on tumor cells. Indeed, activity of the RANKL/RANK pathway in cancer cells has been correlated with tumor progression and advanced disease. Denosumab, a fully human monoclonal antibody against RANKL, inhibits osteoclastogenesis and is widely used not just for the treatment of osteoporosis, but for the prevention of skeletal-related events from bone metastases in solid malignancies such as breast and prostate cancer. The potential effects of denosumab on the immune system have been largely ignored. Nevertheless, with the emergence of immunotherapies for cancer, denosumab may impact the effectiveness of these therapies, especially if they are given in combination. In this article, we review the role of RANKL/RANK in bone, immunity, and cancer. Examining the potential effects of routine treatment with denosumab beyond the bone represents an important area of investigation